Cargando…

Investigation of PALB2 Mutation and Correlation With Immunotherapy Biomarker in Chinese Non-Small Cell Lung Cancer Patients

BACKGROUND: PALB2, a gene in the homologous recombination repair (HRR) pathway of the DNA damage response (DDR), is associated with the efficacy of platinum-based chemotherapy, immunotherapy, and PARP inhibitor therapy in several tumors. However, the PALB2 characteristics, its correlation with immun...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Jiexia, Tang, Shuangfeng, Zhang, Chunning, Li, Mingyao, Zheng, Yating, Hu, Xue, Huang, Mengli, Cheng, Xiangyang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8787147/ https://www.ncbi.nlm.nih.gov/pubmed/35087742 http://dx.doi.org/10.3389/fonc.2021.742833

Ejemplares similares

Case Report: Co-Existence of BRCA2 and PALB2 Germline Mutations in Familial Prostate Cancer With Solitary Lung Metastasis
por: Tang, Tang, et al.
Publicado: (2020)

PALB2 as a factor to predict the prognosis of patients with skull base chordoma
por: Xiong, Yujia, et al.
Publicado: (2022)

Molecular Mechanisms of PALB2 Function and Its Role in Breast Cancer Management
por: Wu, Shijie, et al.
Publicado: (2020)

DDX60 Is Associated With Glioma Malignancy and Serves as a Potential Immunotherapy Biomarker
por: Zhang, Jingwen, et al.
Publicado: (2021)

Complete response to talazoparib in patient with pancreatic adenocarcinoma harboring somatic PALB2 mutation: A case report and literature review
por: Kachmazov, Andrei, et al.
Publicado: (2022)

Germline PALB2 Mutations in Cancers and Its Distinction From Somatic PALB2 Mutations in Breast Cancers
por: Hu, Zhe-Yu, et al.
Publicado: (2020)

Germline PALB2 Mutation in High-Risk Chinese Breast and/or Ovarian Cancer Patients
por: Kwong, Ava, et al.
Publicado: (2021)

Homologous recombination repair gene mutations as a predictive biomarker for immunotherapy in patients with advanced melanoma
por: You, Zhixuan, et al.
Publicado: (2022)

Two Missense Variants Detected in Breast Cancer Probands Preventing BRCA2-PALB2 Protein Interaction
por: Caleca, Laura, et al.
Publicado: (2018)

TCR-T Immunotherapy: The Challenges and Solutions
por: Liu, Yating, et al.
Publicado: (2022)

KEAP1/NFE2L2 Mutations of Liquid Biopsy as Prognostic Biomarkers in Patients With Advanced Non-Small Cell Lung Cancer: Results From Two Multicenter, Randomized Clinical Trials
por: Zhu, Hongyuan, et al.
Publicado: (2021)

Tumour morphology predicts PALB2 germline mutation status
por: Teo, Z L, et al.
Publicado: (2013)

First-line therapeutic strategy for patients with advanced non–small cell lung cancer with Leu858Arg epidermal growth factor receptor mutations: a Bayesian network meta-analysis
por: Chen, Chongxiang, et al.
Publicado: (2022)

Case report: an initially unresectable stage III pulmonary sarcomatoid carcinoma qith EGFR mutation achieving pathological complete response following neoadjuvant therapy with osimertinib plus chemotherapy
por: Liu, Xiguang, et al.
Publicado: (2022)

Perturbation of PALB2 function by the T413S mutation found in small cell lung cancer
por: Bleuyard, Jean-Yves, et al.
Publicado: (2018)

Advanced development of biomarkers for immunotherapy in hepatocellular carcinoma
por: Peng, Xuenan, et al.
Publicado: (2023)

Biomarkers and Future Perspectives for Hepatocellular Carcinoma Immunotherapy
por: He, Yuqing, et al.
Publicado: (2021)

PALB2 mutations in German and Russian patients with bilateral breast cancer
por: Bogdanova, Natalia, et al.
Publicado: (2010)

A PALB2 mutation associated with high risk of breast cancer
por: Southey, Melissa C, et al.
Publicado: (2010)

Beyond Tumor Mutation Burden: Tumor Neoantigen Burden as a Biomarker for Immunotherapy and Other Types of Therapy
por: Wang, Peipei, et al.
Publicado: (2021)

Imaging Biomarkers to Predict and Evaluate the Effectiveness of Immunotherapy in Advanced Non-Small-Cell Lung Cancer
por: Liu, Ying, et al.
Publicado: (2021)

Melanoma Immunotherapy: Next-Generation Biomarkers
por: Hogan, Sabrina A., et al.
Publicado: (2018)

Mutation Status and Immunohistochemical Correlation of KRAS, NRAS, and BRAF in 260 Chinese Colorectal and Gastric Cancers
por: Yang, Qiwei, et al.
Publicado: (2018)

Investigation of Plasma Metabolic and Lipidomic Characteristics of a Chinese Cohort and a Pilot Study of Renal Cell Carcinoma Biomarker
por: Liu, Xiaoyan, et al.
Publicado: (2020)

Phosphogluconate dehydrogenase is a predictive biomarker for immunotherapy in hepatocellular carcinoma
por: Liu, Tiantian, et al.
Publicado: (2022)

Heterozygous mutations in PALB2 cause DNA replication and damage response defects
por: Nikkilä, Jenni, et al.
Publicado: (2013)

Prevalence of PALB2 mutations in Australasian multiple-case breast cancer families
por: Teo, Zhi L, et al.
Publicado: (2013)

Prevalence of PALB2 mutations in Australian familial breast cancer cases and controls
por: Thompson, Ella R., et al.
Publicado: (2015)

Recurrent PALB2 mutations and the risk of cancers of bladder or kidney in Polish population
por: Złowocka-Perłowska, Elżbieta, et al.
Publicado: (2021)

Case Report: Detection of a Novel Germline PALB2 Deletion in a Young Woman With Hereditary Breast Cancer: When the Patient's Phenotype History Doesn't Lie
por: De Angelis, Carmine, et al.
Publicado: (2021)

Review of biomarkers for response to immunotherapy in HNSCC microenvironment
por: Chen, Shaoshi, et al.
Publicado: (2023)

Investigation of the prevalence and clinical implications of ERBB2 exon 16 skipping mutations in Chinese pan-cancer patients
por: Shang, Yanhong, et al.
Publicado: (2023)

Progress on neoadjuvant immunotherapy in resectable non-small cell lung cancer and potential biomarkers
por: Wu, Xinyu, et al.
Publicado: (2023)

Molecular Characterization and Clinical Relevance of Lysine Acetylation Regulators in Urological Cancers
por: Zhang, Jian, et al.
Publicado: (2021)

H2AFZ Is a Prognostic Biomarker Correlated to TP53 Mutation and Immune Infiltration in Hepatocellular Carcinoma
por: Dong, Mingwei, et al.
Publicado: (2021)

Analysis of BRCA Germline Mutations in Chinese Prostate Cancer Patients
por: Chen, Wei, et al.
Publicado: (2022)

Immunotherapy in Non-Small Cell Lung Cancer With Actionable Mutations Other Than EGFR
por: Seegobin, Karan, et al.
Publicado: (2021)

Case report: Rechallenge with EGFR–TKIs after immunotherapy in EGFR–mutated non–small cell lung cancer with leptomeningeal metastasis
por: Qian, Chunfa, et al.
Publicado: (2022)

Pan-Cancer Analysis of IGF-1 and IGF-1R as Potential Prognostic Biomarkers and Immunotherapy Targets
por: Zhang, Yinqi, et al.
Publicado: (2021)

CCNF is a potential pancancer biomarker and immunotherapy target
por: Wei, Lifang, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_m9fc4fprfuo6bgea398hcudppi